Earnings summaries and quarterly performance for Kymera Therapeutics.
Executive leadership at Kymera Therapeutics.
Nello Mainolfi
Detailed
President and Chief Executive Officer
CEO
BA
Brian Adams
Detailed
Chief Legal Officer and Corporate Secretary
BJ
Bruce Jacobs
Detailed
Chief Financial Officer
JG
Jared Gollob
Detailed
Chief Medical Officer
JC
Jeremy Chadwick
Detailed
Chief Operating Officer
NG
Noah Goodman
Detailed
Chief Business Officer
Board of directors at Kymera Therapeutics.
Research analysts who have asked questions during Kymera Therapeutics earnings calls.
JM
Jeet Mukherjee
Leerink Partners
5 questions for KYMR
Also covers: ARVN, BCAB, KURA +4 more
MF
Marc Frahm
TD Cowen
5 questions for KYMR
Also covers: ADAP, AGIO, BPMC +7 more
Andy Chen
Wolfe Research, LLC
4 questions for KYMR
Also covers: ARGX, CRNX, IMVT +7 more
EM
Eliana Merle
UBS
4 questions for KYMR
Also covers: ALNY, APLS, ARVN +17 more
Faisal Khurshid
Leerink Partners
4 questions for KYMR
Also covers: ABCL, ANIP, ASND +7 more
KP
Kalpit Patel
B. Riley Securities
4 questions for KYMR
Also covers: ASND, DERM, EXEL +8 more
Jeff Jones
Oppenheimer & Co. Inc.
3 questions for KYMR
Also covers: ABEO, CLRB, CMMB +8 more
AL
Anna Lee
Truist
2 questions for KYMR
Also covers: CRIS
BC
Bradley Canino
Stifel
2 questions for KYMR
Also covers: ARVN, CELC, KURA +2 more
BC
Brian Cheng
JPMorgan Chase & Co.
2 questions for KYMR
Also covers: ALLO, BEAM, CHRS +11 more
Charles Ndiaye
Stifel Financial Corp.
2 questions for KYMR
Also covers: TVTX
ET
Edward Tenthoff
Piper Sandler Companies
2 questions for KYMR
Also covers: ARVN, ARWR, CAPR +16 more
Eric Joseph
JPMorgan Chase & Co.
2 questions for KYMR
Also covers: BEAM, BLUE, ENTA +9 more
FR
Faisal Rashid
Jefferies
2 questions for KYMR
Geoff Meacham
Citigroup Inc.
2 questions for KYMR
Also covers: ABBV, AMGN, BMY +11 more
JC
Joseph Catanzaro
Wolfe Research, LLC
2 questions for KYMR
Also covers: AADI, CPRX, CRDF +8 more
JR
Judith Rommer
Morgan Stanley
2 questions for KYMR
Kelly Shi
Jefferies
2 questions for KYMR
Also covers: ADCT, AGEN, ALDX +17 more
Michael Schmidt
Guggenheim Securities
2 questions for KYMR
Also covers: ADAP, ADCT, ARVN +20 more
Paul Jeng
Guggenheim Partners
2 questions for KYMR
Also covers: ADAP, BPMC, IMCR +2 more
SL
Sudan Loganadane
Stephens
2 questions for KYMR
SL
Sudan Loganathan
Stephens Inc.
2 questions for KYMR
Also covers: ADCT, ARVN, BPMC +6 more
AS
Alexei Siniakov
Truist Securities
1 question for KYMR
Alex Thompson
Stifel Financial Corp.
1 question for KYMR
Also covers: ARGX, ASND, CRNX +3 more
AN
Andrea Newkirk
Goldman Sachs
1 question for KYMR
Also covers: ABCL, ALKS, ARWR +9 more
BC
Brad Canino
Stifel Financial Corp.
1 question for KYMR
Also covers: BPMC, KYTX, SMMT
Derek Archila
Wells Fargo
1 question for KYMR
Also covers: APLS, ARGX, ARVN +11 more
DS
Dingding Shi
Jefferies
1 question for KYMR
Also covers: ADCT, ASND, AUTL +6 more
EM
Ellie Merle
UBS Group AG
1 question for KYMR
Also covers: ALNY, ALT, ARVN +12 more
EW
Eric Wong
The Goldman Sachs Group, Inc.
1 question for KYMR
Eva Fortea-Verdejo
Wells Fargo Securities
1 question for KYMR
Also covers: EXEL, KNSA, RCUS
GE
Gospel Enyindah-Asonye
Morgan Stanley
1 question for KYMR
Also covers: RGNX, VTYX
H
Hao
Wells Fargo
1 question for KYMR
HS
Hao Shen
Wells Fargo
1 question for KYMR
Judah Frommer
Morgan Stanley
1 question for KYMR
Also covers: APLS, ARQT, ATAI +5 more
Kevin
RBC Capital Markets
1 question for KYMR
Also covers: ARBK, BSEM, CMPS +3 more
KC
Kevin Cullinane
RBC Capital Markets
1 question for KYMR
KD
Kripa Devarakonda
Truist Securities
1 question for KYMR
Also covers: ABCL, ARVN, BMY +5 more
Mayank Mamtani
B. Riley Securities
1 question for KYMR
Also covers: AGEN, ALT, ARWR +18 more
Parth Patel
Morgan Stanley
1 question for KYMR
Also covers: AXSM, INCY
RF
Ron Feiner
Leerink Partners
1 question for KYMR
Also covers: WVE
Sam Slutsky
LifeSci Capital, LLC
1 question for KYMR
Also covers: ALXO, PVLA, RAIN +1 more
SD
Srikripa Devarakonda
Truist Financial Corporation
1 question for KYMR
Also covers: ABCL, ABSI, AFMD +12 more
TA
Tazeen Ahmad
Bank of America
1 question for KYMR
Also covers: ACAD, ALNY, APLS +22 more
VP
Vikram Purohit
Morgan Stanley
1 question for KYMR
Also covers: ABSI, ARGX, ARQT +11 more
Recent press releases and 8-K filings for KYMR.
Kymera Therapeutics Highlights Strategic Focus, Pipeline Progress, and Financial Position
KYMR
New Projects/Investments
Guidance Update
- Kymera Therapeutics has $1.6 billion in cash and a runway into 2029, supporting its strategic shift to focus on IMiD and its robust pipeline.
- The company's lead program, KT-621 (STAT6 targeting), showed promising Phase Ib data in atopic dermatitis (AD) and asthma, with Phase IIb AD trial data expected by mid-2027 and asthma data in later 2027.
- The IRF5 targeting program has commenced dosing in a healthy volunteer study, with data anticipated in the second half of 2026.
- Kymera plans to introduce a new development candidate in the second half of 2026 and has ongoing collaborations, including Sanofi moving a second-generation IRAK4 degrader into Phase I this year.
1 day ago
Kymera Therapeutics provides pipeline updates and financial outlook at Oppenheimer conference
KYMR
New Projects/Investments
Guidance Update
- Kymera Therapeutics is well-capitalized with $1.6 billion in cash, providing a runway into 2029 to fund its pipeline, including Phase 2 studies for STAT6 and the initial Phase 3 study.
- The company's strategic focus has shifted to IMiD, with six programs in the clinic.
- Key pipeline updates include the KT-621 (STAT6) program, with Phase 2b data for atopic dermatitis expected by mid-2027 and for asthma in later 2027.
- The IRF5 targeting program has begun dosing in a healthy volunteer study, with data anticipated in the second half of 2026, preceding a planned proof-of-concept study in lupus.
- Kymera also has partnered programs, including a second-generation IRAK4 degrader with Sanofi entering Phase 1 this year, and a CDK2 program with Gilead.
1 day ago
Kymera Therapeutics Provides Pipeline Update and Strategic Focus at Oppenheimer Healthcare Conference
KYMR
New Projects/Investments
Guidance Update
- Kymera Therapeutics has strategically transitioned its focus to IMiD (immunomodulatory imide drugs) and is well-capitalized with $1.6 billion in cash, providing a runway into 2029.
- The company's lead program, KT-621 (STAT6 targeting), showed promising Phase 1b data in atopic dermatitis (AD) in December 2025, demonstrating strong efficacy comparable to or numerically superior to dupilumab, with Phase 2b studies in AD and asthma currently ongoing.
- Data from the KT-621 AD trial is anticipated by mid-2027, while asthma trial data is expected in later 2027.
- The IRF5 targeting program has commenced dosing in healthy volunteers, with data expected in the second half of 2026 to support a proof-of-concept study in lupus. The company also plans to introduce a new development candidate in the second half of 2026.
1 day ago
Kymera Therapeutics Announces Q4 and Full Year 2025 Results and Pipeline Progress
KYMR
Earnings
New Projects/Investments
Guidance Update
- Kymera Therapeutics reported a net loss of $86,981 for Q4 2025 and $311,351 for the full year 2025, with collaboration revenue of $2,871 in Q4 2025 and $39,211 for the full year.
- The company ended 2025 with $1,619,434 in cash, cash equivalents, and marketable securities, providing a cash runway into 2029.
- Significant clinical progress was made for KT-621 in 2025, including positive Phase 1 healthy volunteer and BroADen Phase 1b AD trial results, and the initiation of Phase 2b trials for Atopic Dermatitis and asthma.
- The IRF5/KT-579 program advanced with the unveiling of its preclinical profile and the commencement of a Phase 1 healthy volunteer trial in February 2026, with data expected in the second half of 2026.
- Kymera also entered a collaboration with Gilead to develop CDK2 molecular glue degraders and saw Sanofi opt-in to KT-485 with plans to advance into Phase 1 testing in 2026.
1 day ago
Kymera Therapeutics Reports Q4 2025 Results, Provides Pipeline Updates and Extends Cash Runway
KYMR
Earnings
Guidance Update
New Projects/Investments
- Kymera Therapeutics ended December 2025 with a cash balance of $1.6 billion, providing a financial runway into 2029.
- For its lead STAT6 degrader, KT-621, the company expects to complete enrollment in the atopic dermatitis Phase IIb study by the end of 2026 with data by mid-2027, and the asthma Phase IIb trial, which dosed its first patient in January 2026, is expected to yield data in late 2027.
- Kymera initiated dosing in the Phase I healthy volunteer study for its IRF5 degrader, KT-579, following FDA IND clearance, with data anticipated in late 2026.
- Q4 2025 collaboration revenue was $2.9 million from the Gilead partnership, with potential for up to $750 million in total milestone payments from Gilead and nearly $1 billion from Sanofi.
- Adjusted cash R&D spend for Q4 2025 was $76.2 million, and adjusted cash G&A spend was $10 million.
1 day ago
Kymera Therapeutics Reports Q4 2025 Financials and Pipeline Progress
KYMR
Earnings
Guidance Update
New Projects/Investments
- Kymera Therapeutics ended 2025 with a cash balance of $1.6 billion, extending its runway into 2029. Collaboration revenue for Q4 2025 was $2.9 million, attributable to the Gilead partnership.
- The company initiated dosing in the Phase 1 healthy volunteer study for KT-579, its IRF5 degrader, after FDA IND clearance, with data expected in the second half of 2026.
- For KT-621, the STAT6 degrader, enrollment in the atopic dermatitis Phase 2b study is expected to complete by the end of 2026 with data by mid-2027, and data from the asthma Phase 2b trial (first patient dosed last month) is anticipated in late 2027.
- Kymera also noted potential future milestones, including up to $750 million from Gilead for the CDK2 program and nearly $1 billion from Sanofi for the IRAK4 degrader, KT-485, which plans to initiate Phase 1 testing this year.
1 day ago
Kymera Therapeutics Reports Strong 2025 Financials and Pipeline Progress in Q4 2025 Earnings Call
KYMR
Earnings
Guidance Update
New Projects/Investments
- Kymera Therapeutics ended 2025 with a strong financial position, reporting a cash balance of $1.6 billion and a runway extending into 2029.
- For Q4 2025, collaboration revenue was $2.9 million, primarily from the Gilead partnership.
- The company made significant pipeline progress, initiating dosing for KT-579 (IRF5 degrader) in a Phase 1 study and advancing KT-621 (STAT6 degrader) with expected completion of enrollment in the atopic dermatitis study in 2026 and data by mid-2027.
- Key partnerships are progressing, with Sanofi expected to start a Phase 1 trial for KT-485 in 2026, potentially yielding nearly $1 billion in milestones, and the Gilead collaboration offering up to $750 million in total milestones for the CDK2 program.
- Kymera plans to announce at least one new program annually, with the next development candidate targeted for the second half of 2026.
1 day ago
Kymera Therapeutics enters new $500 million at-the-market offering and registers significant resale shares
KYMR
- Kymera Therapeutics, Inc. entered into a Sales Agreement with TD Securities (USA) LLC on February 26, 2026, for an "at-the-market" offering program to sell up to $500,000,000 of its common stock.
- Concurrently, the company terminated its previous Open Market Sale Agreement with Jefferies LLC, effective immediately.
- The company also filed a prospectus supplement on February 26, 2026, to register the potential resale by selling stockholders of up to 18,819,826 shares of common stock and 12,565,253 shares of common stock issuable upon the exercise of pre-funded warrants.
1 day ago
Kymera Therapeutics Announces Q4 and Full Year 2025 Financial Results and Business Updates
KYMR
Earnings
Guidance Update
New Projects/Investments
- Kymera Therapeutics reported Q4 2025 collaboration revenues of $2.9 million and a net loss of $87.0 million, with full-year 2025 collaboration revenues of $39.2 million and a net loss of $311.4 million.
- The company concluded 2025 with $1.6 billion in cash, cash equivalents, and investments, extending its cash runway into 2029.
- Significant pipeline advancements include ongoing KT-621 Phase 2b trials in atopic dermatitis and asthma, with data expected by mid-2027 and late-2027 respectively, and the initiation of dosing for KT-579 in a Phase 1 trial with data anticipated in 2H 2026.
- Research and development expenses increased to $316.6 million for the full year 2025, up from $240.2 million in 2024, primarily due to investment in the STAT6 program and discovery initiatives.
1 day ago
Kymera Therapeutics Announces Q4 and Full Year 2025 Financial Results and Business Update
KYMR
Earnings
New Projects/Investments
Management Change
- Kymera Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2025. Key figures are presented in the table below :
| Metric | Q4 2024 | Q4 2025 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Collaboration Revenue ($USD Thousands) | $7,394 | $2,871 | $47,072 | $39,211 |
| Research and Development Expenses ($USD Thousands) | $71,818 | $83,831 | $240,248 | $316,568 |
| General and Administrative Expenses ($USD Thousands) | $16,331 | $16,935 | $63,534 | $68,187 |
| Net Loss ($USD Thousands) | $(70,753) | $(86,981) | $(223,858) | $(311,351) |
- As of December 31, 2025, Kymera had $1.6 billion in cash, cash equivalents, and investments, which is expected to provide a cash runway into 2029.
- The company is advancing its pipeline, with KT-621 (STAT6) Phase 2b trials in atopic dermatitis and asthma ongoing, expecting data by mid-2027 and late-2027 respectively. Additionally, dosing has begun for the KT-579 (IRF5) Phase 1 trial, with data anticipated in 2H26.
- In December 2025, the U.S. Food and Drug Administration granted Fast Track designation to KT-621 for the treatment of moderate to severe atopic dermatitis.
- Dr. Neil Graham was appointed as Chief Development Officer to lead the advancement of Kymera’s oral immunology portfolio.
1 day ago
Quarterly earnings call transcripts for Kymera Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more